Read our latest updates & insights

On 26 June 2024, AbbVie announced that its Epkinly® (epcoritamab) received FDA approval for the treatment of adults with relapsed or refractory follicular lymphoma.  This approval makes Epkinly® the first and only subcutaneous bispecific antibody approved in the US to treat...

On 25 June 2024, Novo Nordisk announced its plan to significantly boost its investment in manufacturing in 2024, allocating USD $6.8 billion towards production.  This is up from USD $3.9 billion the previous year.  

The plan includes a USD $4.1 billion investment to ...

Business Korea reports that Samsung Biologics has entered a contract manufacturing agreement with US based Kiniksa Pharmaceuticals. The deal, valued at approximately USD $156m (211b won) covers the period 21 June 2024 to 31 December 2031. 

This follows the announceme...

On 25 June 2024, Celltrion announced that its Omlyclo (CT-P39), biosimilar to Genentech’s and Novartis’ Xolair® (omalizumab), was approved by the Korean Ministry of Food and Drug Safety for allergic asthma and chronic idiopathic urticaria.  This is the first omalizumab bios...

On 25 June 2024, Evotec announced that its subsidiary, Just – Evotec Biologics, Inc., has been selected by the U.S. Department of Defense to develop an accelerated monoclonal antibody development and manufacturing solution as part of the department’s Manufacturing Optimizat...

On 24 June 2024, Biogen announced its IV tocilizumab, TOFIDENCE™, biosimilar to Roche’s ROACTEMRA®, has been approved by EC.  Tofidence is authorised by the EC for treating moderate to severe active rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, systemic...

On 24 June 2024, Teva Pharmaceuticals announced the US launch of its authorised generic liraglutide injection (1.8 mg) for type 2 diabetes.  Originator Novo Nordisk supplies liraglutide as Victoza®, and Teva’s authorised generic Victoza is the first generic GLP-1 treatment ...

On 24 June 2024, Biocon Biologics announced that it received approval from the European Medicines Agency to manufacture biosimilar bevacizumab from its  multi-product mAbs facility at Bengaluru. 

Biocon received EC authorisation for its Abevmy® (biosimilar bevacizuma...

On 21 June 2025, Argenx announced that the FDA approved a new indication of its VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) for chronic inflammatory demyelinating polyneuropathy (CIDP).  

VYVGART Hytrulo is approved for CIDP, administered as a subcuta...

Results of phase 3 pertuzumab studies comparing Qilu’s QL1209 with Roche’s Perjeta® with trastuzumab and docetaxel were published in the British Journal of Cancer on 21 June 2024.  

The studies demonstrated that QL1209 is equivalent to Perjeta® in safety and efficacy ...